Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
20 June 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Bretaris Genuair Articles
Positive Ph III results for Almirall and Forest's combination COPD drug
16 April 2013
Added benefit of Almirall's aclidinium bromide is not proven, says Germany's IQWiG
10 January 2013
Almirall's aclidinium approved in Europe for COPD maintenance treatment
25 July 2012
Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen
27 May 2012
Showing 1-4 of 4 articles
1
Hot Topics
Most Read
Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
It's official: "obesity is a disease," says AMA
Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
It's official: "obesity is a disease," says AMA
Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD